Retatrutide is an investigational weight loss medication that activates three separate hormone receptors — GLP-1, GIP, and glucagon — compared to tirzepatide's two (GLP-1 and GIP), and early clinical trial data has shown notably greater average weight loss with retatrutide. Importantly, retatrutide is not yet FDA-approved and remains in clinical trials, meaning it isn't currently available by prescription the way semaglutide and tirzepatide are.
How retatrutide's mechanism differs?
Tirzepatide works by activating both GLP-1 and GIP receptors, a dual mechanism that already outperforms single-receptor GLP-1 medications like semaglutide in head-to-head trial data. Retatrutide adds a third receptor target, glucagon, on top of that same GLP-1 and GIP activity. Glucagon receptor activation appears to increase resting energy expenditure and shift how the body metabolizes fat, particularly visceral and liver fat, adding a metabolic mechanism beyond the appetite suppression shared across the whole medication class.
What the trial data has shown so far?
In published Phase 3 trial data, retatrutide has produced meaningfully greater average weight loss than tirzepatide over comparable treatment periods, with retatrutide trial participants losing a notably higher percentage of body weight on average. These are genuinely striking results relative to currently available medications, though it's worth remembering that trial results represent averages, and individual response to any GLP-1 class medication varies significantly.
Why it isn't available yet?
Retatrutide is still working through the FDA approval process, with full approval not expected until sometime in the next one to two years at the earliest, pending continued trial results and regulatory review. Because it hasn't completed this process, retatrutide isn't legally available through a standard prescription today — any product marketed as "retatrutide" outside of a formal clinical trial setting should be treated with real caution, since it hasn't gone through the safety and manufacturing oversight that comes with FDA approval.
What this means if you're considering treatment now?
If you're interested in medically supervised weight loss today, semaglutide and tirzepatide remain the most effective, well-studied, and legally available options, both with substantial published safety and efficacy data behind them. Waiting for retatrutide isn't necessary or, in most cases, advisable if you're a good candidate for treatment now — particularly since currently available medications already produce substantial, clinically meaningful results for the large majority of patients.
What to watch for going forward?
As retatrutide moves through the remainder of its approval process, more data will continue to emerge on its long-term safety profile, which is still less established than tirzepatide's given its more limited history in large patient populations. Once and if it's approved, it will likely become another legitimate option in the growing GLP-1 medication class, but it's not something to delay treatment for today.
How do you talk to your provider?
If you're curious how retatrutide might fit into the future of weight loss treatment, or want to know which currently available medication is right for you now, that's exactly the conversation to have at a consultation with our clinical team.